Researchers at Wake Forest University Baptist Medical Center found promising new molecular targets and treatment approaches for glioblastoma multiforme, the most common form of brain tumor.

Results of three separate studies have been presented at the World Federation of NeuroOncology meeting and the European Association for NeuroOncology meeting, both in Edinburgh, Scotland.

The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs.
Researchers found that a protein, called Fra-1, was effective in controlling vascular endothelial growth factor D ( VEGF-D ), a factor that promotes the growth of new blood vessels in most malignant brain tumors.

The second study was based on findings from previous research by Debinski and colleagues that found that glioblastoma cells have a particular type of receptor for interleukin 13 ( IL-13 ), a protein that regulates the immune system in the body.
IL-13 is a very attractive target for molecular anti-brain tumor therapies and two clinical trials are currently ongoing.
The new study examined the role of proteins called cytokines in augmenting the amount of IL-13 receptor expressed by tumor cells.
The use of these cytokines may improve treatment of glioblastoma cells by increasing the levels of IL-13 receptor in brain tumors and thus making them more accessible to drugs targeting the receptor.

The third research study focused on the search for novel specific molecular markers or targets in brain tumors.
EphA2, a cell membrane-anchored protein-receptor, was shown to be uniformly overexpressed in malignant brain tumors, but not in normal brain tissue.

Source: Wake Forest University Baptist Medical Center, 2005


XagenaMedicine2005